Department of Surgery, Cleveland Clinic, Cleveland, OH.
Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.
J Am Coll Surg. 2018 Apr;226(4):393-403. doi: 10.1016/j.jamcollsurg.2017.12.011. Epub 2017 Dec 21.
Accurate prediction of prognosis for patients with intrahepatic cholangiocarcinoma (ICC) remains a challenge. We sought to define a preoperative risk tool to predict long-term survival after resection of ICC.
Patients who underwent hepatectomy for ICC at 1 of 16 major hepatobiliary centers between 1990 and 2015 were identified. Clinicopathologic data were analyzed and a prognostic model was developed based on the regression β-coefficients on data in training set. The model was subsequently assessed using a validation set.
Among 538 patients, most patients had a solitary tumor (median tumor number 1; interquartile range 1 to 2) and median tumor size was 5.7 cm (interquartile range 4.0 to 8.0 cm). Median and 5-year overall survival was 39.0 months and 39.0%, respectively. On multivariable analyses, preoperative factors associated with long-term survival included tumor size (hazard ratio [HR] 1.12; 95% CI 1.06 to 1.18), natural logarithm carbohydrate antigen 19-9 level (HR 1.33; 95% CI 1.22 to 1.45), albumin level (HR 0.76; 95% CI 0.55 to 0.99), and neutrophil to lymphocyte ratio (HR 1.05; 95% CI 1.02 to 1.09). A weighted composite prognostic score was constructed based on these factors: [9 + (1.12 × tumor size) + (2.81 × natural logarithm carbohydrate antigen 19-9) + (0.50 × neutrophil to lymphocyte ratio) + (-2.79 × albumin)]. The model demonstrated good performance in the testing (area under the curve 0.696) and validation (0.691) datasets. The model performed better than both the T categories (area under the curve 0.532) and the cumulative stage classifications in the American Joint Committee on Cancer staging manual, 8th edition (area under the curve 0.559). When assessing risk of death within 1 year of operation, a risk score ≥25 had a positive predictive value of 59.8% compared with a positive predictive value of 35.3% for American Joint Committee on Cancer staging manual, 8th edition T4 disease and 31.8% for stage IIIB disease.
Postsurgical long-term outcomes could be predicted using a composite weighted scoring system based on preoperative clinical parameters. The preoperative risk model can be used to inform patient to provider conversations and expectations before operation.
准确预测肝内胆管癌(ICC)患者的预后仍然是一个挑战。我们试图定义一种术前风险工具,以预测 ICC 切除术后的长期生存。
在 1990 年至 2015 年间,在 16 个主要肝胆中心中的 1 个中心接受肝切除术治疗 ICC 的患者被确定。分析了临床病理数据,并根据训练集数据中的回归β系数建立了预后模型。该模型随后在验证集中进行了评估。
在 538 名患者中,大多数患者有单个肿瘤(中位数肿瘤数为 1;四分位距 1 至 2),中位数肿瘤大小为 5.7 cm(四分位距 4.0 至 8.0 cm)。中位和 5 年总生存率分别为 39.0 个月和 39.0%。多变量分析显示,与长期生存相关的术前因素包括肿瘤大小(风险比 [HR] 1.12;95%CI 1.06 至 1.18)、自然对数碳水化合物抗原 19-9 水平(HR 1.33;95%CI 1.22 至 1.45)、白蛋白水平(HR 0.76;95%CI 0.55 至 0.99)和中性粒细胞与淋巴细胞比值(HR 1.05;95%CI 1.02 至 1.09)。基于这些因素构建了加权综合预后评分:[9 +(1.12×肿瘤大小)+(2.81×自然对数碳水化合物抗原 19-9)+(0.50×中性粒细胞与淋巴细胞比值)+(-2.79×白蛋白)]。该模型在测试(曲线下面积 0.696)和验证(0.691)数据集上均表现出良好的性能。该模型的表现优于 T 分期(曲线下面积 0.532)和美国癌症联合委员会(AJCC)第 8 版分期手册中的累积分期分类(曲线下面积 0.559)。当评估术后 1 年内死亡风险时,评分≥25 的阳性预测值为 59.8%,而 AJCC 第 8 版 T4 疾病的阳性预测值为 35.3%,IIIb 期疾病的阳性预测值为 31.8%。
可以使用基于术前临床参数的综合加权评分系统预测术后长期预后。术前风险模型可用于在手术前为患者和提供者提供信息并告知其预期。